When we turn our attention to emerging global threats, we know what to expect: grim statistics, dire predictions, and—perhaps worst of all—disturbing revelations that no preventive or corrective ...

Results for talquetamab presented at the 64th American Society of Hematology Annual Meeting and Exposition showed that about 70% of patients with multiple myeloma had responses. More than 70% of ...

The study also found that patients with a later best confirmed response to therapy demonstrated improved outcomes compared with patients who experienced an early best confirmed response. A secondary ...